Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486981 | 0.87 | CNR1 (0.50) | DPP4CNR1CNR2 | |
| SCHEMBL4559521 | 0.86 | CNR1 (0.52) | DPP4CNR1CNR2 | |
| SCHEMBL4480277 | 0.77 | ALDH1A1 (0.51) | CNR1CNR2 | |
| SCHEMBL5043907 | 0.75 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL5263967 | 0.74 | DPP4 (0.43) | DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL2840745 | 0.72 | DPP4 (0.42) | DPP4DPP8 | |
| SCHEMBL5276319 | 0.72 | DPP4 (0.44) | DPP4DPP8 | |
| SCHEMBL4477519 | 0.71 | CNR1 (0.57) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL2842001 | 0.71 | DPP4 (0.43) | DPP4DPP8 | |
| SCHEMBL5041885 | 0.70 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618991-B2 | Heterocyclic derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20080269303-A1 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1966173-A2 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068815-A2 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269303-A1 | HETEROCYCLIC DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, NQO1 | DPP4 1868/4885CNR1 12/4885CNR2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.